The FDA said certain lots of AstraZeneca's COVID-19 vaccine manufactured at Emergent Biosolutions' Baltimore facility are fit to be shipped outside the US, as reported Financial Post.

The plant was producing vaccines for AstraZeneca and Johnson & Johnson but US health regulators in April halted operations following a discovery that Johnson & Johnson's vaccine was contaminated with material used in the AstraZeneca doses.

"The agency conducted a thorough review of facility records and the results of quality testing performed by the manufacturer and reached its decision based on this review, taking into consideration the current worldwide COVID-19 public health emergency," said FDA spokesperson Stephanie Caccomo.